Pharmaceutical companies extend their AI-intelligence to create more effective trials.

"New (DNA-based) ways of drugs discovery render more (potential) medications for ever more personalized medicines – It impacts their organizational and marketing substantially.
How is the pharmaceutical industry going to support patients effectively, when numbers of targeted patients appear to fall because of (the need of) individualization by personalized medicine?
Pharaphorum writes: “It has been announced that global management consulting and technology firm ZS Associates has reached a definitive agreement to acquire Trials.ai, an intelligent study design company that uses artificial intelligence (AI) to optimise the experience and deliver pharmaceuticals to market faster. Michael Martin, principal at the 1983-founded ZS and lead of its clinical development practice area, said: “Clinical studies too often struggle to find participants and encounter delays, but life sciences companies will now be able to use the ZS|Trials.ai solution to identify risk and opportunities, model operational trade-offs in real-time and better see how study decisions will affect participants, sites, and sponsors.”
New ways of drug discoveries deliver more potential medication opportunities and specifically so in close adaptation to personal, physical and DNA-related characteristics of patients: personalized medication.
How will the pharmaceutical industry manage the marketing and customer-servicing consequences set by these new personalized drugs: what will be their patient- as well as healthcare-professionals-services in the real world context? And how will these be delivered?..." Lire la suite